{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T09:36:23Z","timestamp":1792402583506,"version":"4.4.0"},"reference-count":167,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Pharmacology"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.coph.2017.02.001","type":"journal-article","created":{"date-parts":[[2017,3,10]],"date-time":"2017-03-10T23:20:48Z","timestamp":1489188048000},"page":"96-110","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":102,"special_numbering":"C","title":["The role of GPCRs in neurodegenerative diseases: avenues for therapeutic intervention"],"prefix":"10.1016","volume":"32","author":[{"given":"Yunhong","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Todd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amantha","family":"Thathiah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coph.2017.02.001_bib0005","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1172\/JCI200317522","article-title":"Neurodegeneration: what is it and where are we?","volume":"111","author":"Przedborski","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.coph.2017.02.001_bib0010","doi-asserted-by":"crossref","first-page":"465","DOI":"10.31887\/DCNS.2013.15.4\/sarlt","article-title":"Non-Alzheimer\u2019s disease-related memory impairment and dementia","volume":"15","author":"Arlt","year":"2013","journal-title":"Dialogues Clin Neurosci"},{"key":"10.1016\/j.coph.2017.02.001_bib0015","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1093\/cercor\/bhn113","article-title":"The cortical signature of Alzheimer\u2019s disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals","volume":"19","author":"Dickerson","year":"2009","journal-title":"Cereb Cortex"},{"issue":"Suppl. 13","key":"10.1016\/j.coph.2017.02.001_bib0020","first-page":"S339","article-title":"The growing burden of Alzheimer\u2019s disease","volume":"17","author":"Lopez","year":"2011","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.coph.2017.02.001_bib0025","doi-asserted-by":"publisher","first-page":"a006189","DOI":"10.1101\/cshperspect.a006189","article-title":"Neuropathological alterations in Alzheimer disease","volume":"1","author":"Serrano-Pozo","year":"2011","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.coph.2017.02.001_bib0030","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1097\/WAD.0000000000000034","article-title":"Diagnostic criteria for vascular cognitive disorders: a VASCOG statement","volume":"28","author":"Sachdev","year":"2014","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"10.1016\/j.coph.2017.02.001_sbref0035","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s00401-016-1571-z","article-title":"Neuropathological diagnosis of vascular cognitive impairment and vascular dementia with implications for Alzheimer\u2019s disease","volume":"131","author":"Kalaria","year":"2016","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.coph.2017.02.001_sbref0040","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s12031-016-0799-3","article-title":"Magnetic resonance imaging of vascular contributions to cognitive impairment and dementia","volume":"60","author":"Yassi","year":"2016","journal-title":"J Mol Neurosci"},{"key":"10.1016\/j.coph.2017.02.001_bib0045","doi-asserted-by":"publisher","first-page":"f4827","DOI":"10.1136\/bmj.f4827","article-title":"Frontotemporal dementia","volume":"347","author":"Warren","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.coph.2017.02.001_bib0050","doi-asserted-by":"publisher","first-page":"141","DOI":"10.2217\/nmt.11.9","article-title":"Management of frontotemporal dementia: targeting symptom management in such a heterogeneous disease requires a wide range of therapeutic options","volume":"1","author":"Jicha","year":"2011","journal-title":"Neurodegener Dis Manag"},{"key":"10.1016\/j.coph.2017.02.001_bib0055","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.3233\/JAD-2010-101413","article-title":"Intra-familial clinical heterogeneity due to FTLD-U with TDP-43 proteinopathy caused by a novel deletion in progranulin gene (PGRN)","volume":"22","author":"Gabryelewicz","year":"2010","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.coph.2017.02.001_bib0060","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1172\/JCI24761","article-title":"The genetic epidemiology of neurodegenerative disease","volume":"115","author":"Bertram","year":"2005","journal-title":"J Clin Invest"},{"key":"10.1016\/j.coph.2017.02.001_bib0065","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","article-title":"Parkinson\u2019s disease","volume":"386","author":"Kalia","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2017.02.001_bib0070","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/nrneurol.2014.24","article-title":"Huntington disease: natural history, biomarkers and prospects for therapeutics","volume":"10","author":"Ross","year":"2014","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.coph.2017.02.001_bib0075","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/ng0893-398","article-title":"The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington\u2019s disease","volume":"4","author":"Andrew","year":"1993","journal-title":"Nat Genet"},{"key":"10.1016\/j.coph.2017.02.001_bib0080","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1523\/JNEUROSCI.19-07-02522.1999","article-title":"Nuclear and neuropil aggregates in Huntington\u2019s disease: relationship to neuropathology","volume":"19","author":"Gutekunst","year":"1999","journal-title":"J Neurosci"},{"key":"10.1016\/j.coph.2017.02.001_bib0085","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neuint.2016.09.005","article-title":"G-protein coupled receptors as therapeutic targets for neurodegenerative and cerebrovascular diseases","volume":"101","author":"Guerram","year":"2016","journal-title":"Neurochem Int"},{"key":"10.1016\/j.coph.2017.02.001_bib0090","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1016\/j.biotechadv.2013.08.017","article-title":"An overview of the diverse roles of G-protein coupled receptors (GPCRs) in the pathophysiology of various human diseases","volume":"31","author":"Heng","year":"2013","journal-title":"Biotechnol Adv"},{"key":"10.1016\/j.coph.2017.02.001_bib0095","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/nrm908","article-title":"Seven-transmembrane receptors","volume":"3","author":"Pierce","year":"2002","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.coph.2017.02.001_bib0100","doi-asserted-by":"publisher","first-page":"4903","DOI":"10.1073\/pnas.0230374100","article-title":"The G protein-coupled receptor repertoires of human and mouse","volume":"100","author":"Vassilatis","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coph.2017.02.001_bib0105","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1210\/me.2009-0473","article-title":"The year in G protein-coupled receptor research","volume":"24","author":"Millar","year":"2010","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.coph.2017.02.001_bib0110","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1136\/jnnp.71.4.441","article-title":"Magnetic resonance imaging of the entorhinal cortex and hippocampus in mild cognitive impairment and Alzheimer\u2019s disease","volume":"71","author":"Du","year":"2001","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.coph.2017.02.001_bib0115","doi-asserted-by":"publisher","first-page":"315","DOI":"10.2174\/1570159X11311030006","article-title":"Acetylcholinesterase inhibitors: pharmacology and toxicology","volume":"11","author":"Colovic","year":"2013","journal-title":"Curr Neuropharmacol"},{"key":"10.1016\/j.coph.2017.02.001_bib0120","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/ana.24001","article-title":"The therapeutics of Alzheimer\u2019s disease: where we stand and where we are heading","volume":"74","author":"Selkoe","year":"2013","journal-title":"Ann Neurol"},{"key":"10.1016\/j.coph.2017.02.001_bib0125","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/aps.2009.24","article-title":"Molecular mechanisms of excitotoxicity and their relevance to pathogenesis of neurodegenerative diseases","volume":"30","author":"Dong","year":"2009","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.coph.2017.02.001_bib0130","doi-asserted-by":"publisher","first-page":"891","DOI":"10.2217\/1745509X.2.6.891","article-title":"Memantine in the treatment of Alzheimer\u2019s disease","volume":"2","author":"Porsteinsson","year":"2006","journal-title":"Aging Health"},{"key":"10.1016\/j.coph.2017.02.001_bib0135","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/BF03033787","article-title":"Neuroprotective and symptomatological action of memantine relevant for Alzheimer\u2019s disease\u2014a unified glutamatergic hypothesis on the mechanism of action","volume":"2","author":"Danysz","year":"2000","journal-title":"Neurotox Res"},{"key":"10.1016\/j.coph.2017.02.001_bib0140","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1056\/NEJMoa013128","article-title":"Memantine in moderate-to-severe Alzheimer\u2019s disease","volume":"348","author":"Reisberg","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2017.02.001_bib0145","doi-asserted-by":"publisher","first-page":"948","DOI":"10.7150\/ijbs.6426","article-title":"Glutamate, glutamate receptors, and downstream signaling pathways","volume":"9","author":"Willard","year":"2013","journal-title":"Int J Biol Sci"},{"key":"10.1016\/j.coph.2017.02.001_bib0150","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/1756-6606-7-40","article-title":"Metabotropic glutamate receptor 5 knockout reduces cognitive impairment and pathogenesis in a mouse model of Alzheimer\u2019s disease","volume":"7","author":"Hamilton","year":"2014","journal-title":"Mol Brain"},{"key":"10.1016\/j.coph.2017.02.001_bib0155","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/j.neuron.2013.06.036","article-title":"Metabotropic glutamate receptor 5 is a coreceptor for Alzheimer abeta oligomer bound to cellular prion protein","volume":"79","author":"Um","year":"2013","journal-title":"Neuron"},{"key":"10.1016\/j.coph.2017.02.001_bib0160","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1016\/j.celrep.2016.04.077","article-title":"Chronic pharmacological mGluR5 inhibition prevents cognitive impairment and reduces pathogenesis in an Alzheimer disease mouse model","volume":"15","author":"Hamilton","year":"2016","journal-title":"Cell Rep"},{"key":"10.1016\/j.coph.2017.02.001_bib0165","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.neuropharm.2014.05.013","article-title":"SSP-002392, a new 5-HT4 receptor agonist, dose-dependently reverses scopolamine-induced learning and memory impairments in C57Bl\/6 mice","volume":"85","author":"Lo","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.coph.2017.02.001_bib0170","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.neuropharm.2012.06.007","article-title":"Stimulation of serotonin 2A receptors facilitates consolidation and extinction of fear memory in C57BL\/6J mice","volume":"64","author":"Zhang","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.coph.2017.02.001_bib0175","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1091\/mbc.E06-12-1080","article-title":"5-Hydroxytryptamine 4 receptor activation of the extracellular signal-regulated kinase pathway depends on Src activation but not on G protein or beta-arrestin signaling","volume":"18","author":"Barthet","year":"2007","journal-title":"Mol Biol Cell"},{"key":"10.1016\/j.coph.2017.02.001_bib0180","doi-asserted-by":"publisher","first-page":"21004","DOI":"10.1074\/jbc.M512096200","article-title":"5-HT2A receptor induces ERK phosphorylation and proliferation through ADAM-17 tumor necrosis factor-alpha-converting enzyme (TACE) activation and heparin-bound epidermal growth factor-like growth factor (HB-EGF) shedding in mesangial cells","volume":"281","author":"Gooz","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1016\/j.coph.2017.02.001_bib0185","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/sj.npp.1300024","article-title":"Selective 5-HT1A antagonists WAY 100635 and NAD-299 attenuate the impairment of passive avoidance caused by scopolamine in the rat","volume":"28","author":"Misane","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.coph.2017.02.001_bib0190","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.jphs.2015.02.006","article-title":"Novel 5-HT5A receptor antagonists ameliorate scopolamine-induced working memory deficit in mice and reference memory impairment in aged rats","volume":"127","author":"Yamazaki","year":"2015","journal-title":"J Pharmacol Sci"},{"key":"10.1016\/j.coph.2017.02.001_bib0195","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/S0014-2999(98)00744-4","article-title":"The human 5-ht5A receptor couples to Gi\/Go proteins and inhibits adenylate cyclase in HEK 293 cells","volume":"361","author":"Francken","year":"1998","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.coph.2017.02.001_bib0200","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.bbr.2013.05.051","article-title":"Role of 5-HT5A receptors in the consolidation of memory","volume":"252","author":"Gonzalez","year":"2013","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.coph.2017.02.001_bib0205","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1111\/j.1476-5381.2012.02022.x","article-title":"5-HT(6) receptor agonists and antagonists enhance learning and memory in a conditioned emotion response paradigm by modulation of cholinergic and glutamatergic mechanisms","volume":"167","author":"Woods","year":"2012","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.coph.2017.02.001_bib0210","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/alzrt169","article-title":"5-HT6 receptors and Alzheimer\u2019s disease","volume":"5","author":"Ramirez","year":"2013","journal-title":"Alzheimer\u2019s Res Ther"},{"key":"10.1016\/j.coph.2017.02.001_bib0215","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/978-3-642-45106-5_9","article-title":"BDNF and synaptic plasticity, cognitive function, and dysfunction","volume":"220","author":"Lu","year":"2014","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.coph.2017.02.001_bib0220","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1017\/S146114570999054X","article-title":"Signalling pathways associated with 5-HT6 receptors: relevance for cognitive effects","volume":"13","author":"Marcos","year":"2010","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.coph.2017.02.001_bib0225","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1111\/j.1750-3639.2007.00112.x","article-title":"Up-regulation of adenosine receptors in the frontal cortex in Alzheimer\u2019s disease","volume":"18","author":"Albasanz","year":"2008","journal-title":"Brain Pathol"},{"key":"10.1016\/j.coph.2017.02.001_bib0230","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/nn.3623","article-title":"Post-study caffeine administration enhances memory consolidation in humans","volume":"17","author":"Borota","year":"2014","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.coph.2017.02.001_bib0235","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.neuroscience.2006.07.021","article-title":"Caffeine protects Alzheimer\u2019s mice against cognitive impairment and reduces brain beta-amyloid production","volume":"142","author":"Arendash","year":"2006","journal-title":"Neuroscience"},{"key":"10.1016\/j.coph.2017.02.001_bib0240","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.expneurol.2006.08.008","article-title":"Caffeine and adenosine A(2a) receptor antagonists prevent beta-amyloid (25-35)-induced cognitive deficits in mice","volume":"203","author":"Dall\u2019Igna","year":"2007","journal-title":"Exp Neurol"},{"key":"10.1016\/j.coph.2017.02.001_sbref0245","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/nn.3930","article-title":"Astrocytic adenosine receptor A2A and Gs-coupled signaling regulate memory","volume":"18","author":"Orr","year":"2015","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.coph.2017.02.001_bib0250","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1002\/neu.20213","article-title":"Activation of receptors negatively coupled to adenylate cyclase is required for induction of long-term synaptic depression at Schaffer collateral-CA1 synapses","volume":"66","author":"Santschi","year":"2006","journal-title":"J Neurobiol"},{"key":"10.1016\/j.coph.2017.02.001_bib0255","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/nm.3023","article-title":"Beta-arrestin 2 regulates Abeta generation and gamma-secretase activity in Alzheimer\u2019s disease","volume":"19","author":"Thathiah","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.coph.2017.02.001_bib0260","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1126\/science.1160649","article-title":"The orphan G protein-coupled receptor 3 modulates amyloid-beta peptide generation in neurons","volume":"323","author":"Thathiah","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.coph.2017.02.001_sbref0265","doi-asserted-by":"publisher","first-page":"309ra164","DOI":"10.1126\/scitranslmed.aab3492","article-title":"Loss of GPR3 reduces the amyloid plaque burden and improves memory in Alzheimer\u2019s disease mouse models","volume":"7","author":"Huang","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coph.2017.02.001_bib0270","doi-asserted-by":"publisher","first-page":"58","DOI":"10.3389\/fnagi.2016.00058","article-title":"G protein-coupled receptors (GPCRs) in Alzheimer\u2019s disease: a focus on BACE1 related GPCRs","volume":"8","author":"Zhao","year":"2016","journal-title":"Front Aging Neurosci"},{"key":"10.1016\/j.coph.2017.02.001_bib0275","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/nrn2977","article-title":"The role of G protein-coupled receptors in the pathology of Alzheimer\u2019s disease","volume":"12","author":"Thathiah","year":"2011","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.coph.2017.02.001_bib0280","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1002\/ajmg.b.32046","article-title":"Association of CRHR1 and CRHR2 with major depressive disorder and panic disorder in a Japanese population","volume":"159b","author":"Ishitobi","year":"2012","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"10.1016\/j.coph.2017.02.001_sbref0285","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.15252\/embj.201488795","article-title":"The stress response neuropeptide CRF increases amyloid-beta production by regulating gamma-secretase activity","volume":"34","author":"Park","year":"2015","journal-title":"EMBO J"},{"key":"10.1016\/j.coph.2017.02.001_bib0290","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1001\/archpsyc.63.2.161","article-title":"Increased hippocampal plaques and tangles in patients with Alzheimer disease with a lifetime history of major depression","volume":"63","author":"Rapp","year":"2006","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.coph.2017.02.001_sbref0295","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.3233\/JAD-142844","article-title":"Impact of CRFR1 ablation on amyloid-beta production and accumulation in a mouse model of Alzheimer\u2019s disease","volume":"45","author":"Campbell","year":"2015","journal-title":"J Alzheimer\u2019s Dis"},{"key":"10.1016\/j.coph.2017.02.001_bib0300","doi-asserted-by":"publisher","first-page":"4711","DOI":"10.1007\/s00213-014-3629-8","article-title":"Effects of corticotrophin-releasing factor receptor 1 antagonists on amyloid-beta and behavior in Tg2576 mice","volume":"231","author":"Dong","year":"2014","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.coph.2017.02.001_bib0305","doi-asserted-by":"crossref","first-page":"5295","DOI":"10.1523\/JNEUROSCI.23-12-05295.2003","article-title":"Increased depression-like behaviors in corticotropin-releasing factor receptor-2-deficient mice: sexually dichotomous responses","volume":"23","author":"Bale","year":"2003","journal-title":"J Neurosci"},{"key":"10.1016\/j.coph.2017.02.001_bib0310","doi-asserted-by":"crossref","first-page":"31","DOI":"10.31887\/DCNS.2002.4.1\/jreul","article-title":"On the role of corticotropin-releasing hormone receptors in anxiety and depression","volume":"4","author":"Reul","year":"2002","journal-title":"Dialogues Clin Neurosci"},{"key":"10.1016\/j.coph.2017.02.001_bib0315","doi-asserted-by":"crossref","first-page":"6340","DOI":"10.1523\/JNEUROSCI.15-10-06340.1995","article-title":"Localization of novel corticotropin-releasing factor receptor (CRF2) mRNA expression to specific subcortical nuclei in rat brain: comparison with CRF1 receptor mRNA expression","volume":"15","author":"Chalmers","year":"1995","journal-title":"J Neurosci"},{"key":"10.1016\/j.coph.2017.02.001_bib0320","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1192\/bjp.180.2.140","article-title":"Frontotemporal dementia","volume":"180","author":"Snowden","year":"2002","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.coph.2017.02.001_bib0325","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1212\/WNL.51.6.1546","article-title":"Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria","volume":"51","author":"Neary","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.coph.2017.02.001_bib0330","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1093\/brain\/awr171","article-title":"The effects of oxytocin on social cognition and behaviour in frontotemporal dementia","volume":"134","author":"Jesso","year":"2011","journal-title":"Brain"},{"key":"10.1016\/j.coph.2017.02.001_bib0335","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1126\/science.1158668","article-title":"Oxytocin, vasopressin, and the neurogenetics of sociality","volume":"322","author":"Donaldson","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.coph.2017.02.001_bib0340","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.neuron.2008.04.009","article-title":"Oxytocin shapes the neural circuitry of trust and trust adaptation in humans","volume":"58","author":"Baumgartner","year":"2008","journal-title":"Neuron"},{"key":"10.1016\/j.coph.2017.02.001_bib0345","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1037\/bne0000074","article-title":"Oxytocin reduces amygdala activity, increases social interactions, and reduces anxiety-like behavior irrespective of NMDAR antagonism","volume":"129","author":"Sobota","year":"2015","journal-title":"Behav Neurosci"},{"key":"10.1016\/j.coph.2017.02.001_bib0350","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.mcn.2006.01.006","article-title":"Oxytocin and estrogen promote rapid formation of functional GABA synapses in the adult supraoptic nucleus","volume":"31","author":"Theodosis","year":"2006","journal-title":"Mol Cell Neurosci"},{"key":"10.1016\/j.coph.2017.02.001_bib0355","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1212\/WNL.0000000000001133","article-title":"Oxytocin for frontotemporal dementia: a randomized dose-finding study of safety and tolerability","volume":"84","author":"Finger","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.coph.2017.02.001_bib0360","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1002\/ana.20365","article-title":"Glucose metabolism and serotonin receptors in the frontotemporal lobe degeneration","volume":"57","author":"Franceschi","year":"2005","journal-title":"Ann Neurol"},{"issue":"Suppl. 1","key":"10.1016\/j.coph.2017.02.001_bib0365","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1159\/000051219","article-title":"Neurochemical features of frontotemporal dementia","volume":"10","author":"Procter","year":"1999","journal-title":"Dement Geriatr Cogn Disord"},{"key":"10.1016\/j.coph.2017.02.001_bib0370","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s00213-007-0992-8","article-title":"Imbalance of a serotonergic system in frontotemporal dementia: implication for pharmacotherapy","volume":"196","author":"Bowen","year":"2008","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.coph.2017.02.001_bib0375","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1523\/JNEUROSCI.12-02-00440.1992","article-title":"Distribution and cellular localization of mRNA coding for 5-HT1A receptor in the rat brain: correlation with receptor binding","volume":"12","author":"Pompeiano","year":"1992","journal-title":"J Neurosci"},{"key":"10.1016\/j.coph.2017.02.001_bib0380","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.tips.2008.07.001","article-title":"A role for the 5-HT(1A), 5-HT4 and 5-HT6 receptors in learning and memory","volume":"29","author":"King","year":"2008","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.coph.2017.02.001_bib0385","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/6338","article-title":"Activation of NMDA receptors reverses desensitization of mGluR5 in native and recombinant systems","volume":"2","author":"Alagarsamy","year":"1999","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.coph.2017.02.001_bib0390","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/S0091-3057(02)00826-2","article-title":"NMDA-induced phosphorylation and regulation of mGluR5","volume":"73","author":"Alagarsamy","year":"2002","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.coph.2017.02.001_sbref0395","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1007\/s00429-014-0978-3","article-title":"In vivo characterization of metabotropic glutamate receptor type 5 abnormalities in behavioral variant FTD","volume":"221","author":"Leuzy","year":"2016","journal-title":"Brain Struct Funct"},{"key":"10.1016\/j.coph.2017.02.001_bib0400","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1093\/cercor\/bhi087","article-title":"Bursting of prefrontal cortex neurons in awake rats is regulated by metabotropic glutamate 5 (mGlu5) receptors: rate-dependent influence and interaction with NMDA receptors","volume":"16","author":"Homayoun","year":"2006","journal-title":"Cereb Cortex"},{"key":"10.1016\/j.coph.2017.02.001_bib0405","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1124\/jpet.104.079244","article-title":"A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models","volume":"313","author":"Kinney","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.coph.2017.02.001_bib0410","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S0891-0618(01)00122-3","article-title":"D1 and D2 dopamine receptor mRNA expression in whole hemisphere sections of the human brain","volume":"22","author":"Hurd","year":"2001","journal-title":"J Chem Neuroanat"},{"key":"10.1016\/j.coph.2017.02.001_bib0415","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1177\/070674370204700106","article-title":"Atypical antipsychotics: mechanism of action","volume":"47","author":"Seeman","year":"2002","journal-title":"Can J Psychiatry"},{"key":"10.1016\/j.coph.2017.02.001_bib0420","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1176\/appi.ajp.158.3.360","article-title":"Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics? A new hypothesis","volume":"158","author":"Kapur","year":"2001","journal-title":"Am J Psychiatry"},{"issue":"Pt. 6","key":"10.1016\/j.coph.2017.02.001_bib0425","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1093\/brain\/119.6.2085","article-title":"Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington\u2019s disease","volume":"119","author":"Antonini","year":"1996","journal-title":"Brain"},{"key":"10.1016\/j.coph.2017.02.001_bib0430","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/0022-510X(88)90020-2","article-title":"Studies on neurotransmitter markers of the basal ganglia in Pick\u2019s disease, with special reference to dopamine reduction","volume":"83","author":"Kanazawa","year":"1988","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.coph.2017.02.001_bib0435","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1002\/1531-8249(199911)46:5<708::AID-ANA5>3.0.CO;2-K","article-title":"FTDP-17: an early-onset phenotype with parkinsonism and epileptic seizures caused by a novel mutation","volume":"46","author":"Sperfeld","year":"1999","journal-title":"Ann Neurol"},{"key":"10.1016\/j.coph.2017.02.001_bib0440","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/S1474-4422(15)00019-8","article-title":"Apathy in Parkinson\u2019s disease: clinical features, neural substrates, diagnosis, and treatment","volume":"14","author":"Pagonabarraga","year":"2015","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.coph.2017.02.001_sbref0445","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1159\/000445873","article-title":"Agomelatine improves apathy in frontotemporal dementia","volume":"16","author":"Callegari","year":"2016","journal-title":"Neurodegener Dis"},{"key":"10.1016\/j.coph.2017.02.001_bib0450","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-9338(14)78444-5","article-title":"EPA-1197-agomelatine for treating apathy in Alzheimer\u2019s disease","volume":"29","author":"Karaiskos","year":"2014","journal-title":"Eur Psychiatry"},{"key":"10.1016\/j.coph.2017.02.001_bib0455","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1097\/JCP.0000000000000404","article-title":"Agomelatine for depression in Parkinson disease: additional effect on sleep and motor dysfunction","volume":"35","author":"Avila","year":"2015","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.coph.2017.02.001_bib0460","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/S1474-4422(02)00190-4","article-title":"Subcortical ischaemic vascular dementia","volume":"1","author":"Roman","year":"2002","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.coph.2017.02.001_bib0465","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/0014-2999(92)90457-F","article-title":"SDZ ENS 163, a selective muscarinic M1 receptor agonist, facilitates the induction of long-term potentiation in rat hippocampal slices","volume":"222","author":"Boddeke","year":"1992","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.coph.2017.02.001_bib0470","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/0006-8993(96)00400-3","article-title":"Relationship between cholinergic dysfunction and discrimination learning disabilities in Wistar rats following chronic cerebral hypoperfusion","volume":"729","author":"Tanaka","year":"1996","journal-title":"Brain Res"},{"key":"10.1016\/j.coph.2017.02.001_bib0475","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/0168-0102(95)01017-3","article-title":"Preventive effects of bifemelane hydrochloride on decreased levels of muscarinic acetylcholine receptor and its mRNA in a rat model of chronic cerebral hypoperfusion","volume":"24","author":"Kondo","year":"1996","journal-title":"Neurosci Res"},{"key":"10.1016\/j.coph.2017.02.001_bib0480","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1101\/lm.166906","article-title":"Age-related enhancement of a protein synthesis-dependent late phase of LTP induced by low frequency paired-pulse stimulation in hippocampus","volume":"13","author":"Huang","year":"2006","journal-title":"Learn Mem"},{"key":"10.1016\/j.coph.2017.02.001_bib0485","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1126\/science.1172545","article-title":"Dopamine controls persistence of long-term memory storage","volume":"325","author":"Rossato","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.coph.2017.02.001_sbref0490","first-page":"709","article-title":"Involvement of dopamine D1 receptors of the hippocampal dentate gyrus in spatial learning and memory deficits in a rat model of vascular dementia","volume":"69","author":"Wan","year":"2014","journal-title":"Pharmazie"},{"key":"10.1016\/j.coph.2017.02.001_bib0495","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.brainres.2008.02.008","article-title":"The role of GABAergic transmission in the dentate gyrus on acquisition, consolidation and retrieval of an inhibitory avoidance learning and memory task in the rat","volume":"1204","author":"Shahidi","year":"2008","journal-title":"Brain Res"},{"key":"10.1016\/j.coph.2017.02.001_bib0500","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1007\/s12035-014-8736-3","article-title":"Activation of GABAB receptors ameliorates cognitive impairment via restoring the balance of HCN1\/HCN2 surface expression in the hippocampal CA1 area in rats with chronic cerebral hypoperfusion","volume":"50","author":"Li","year":"2014","journal-title":"Mol Neurobiol"},{"key":"10.1016\/j.coph.2017.02.001_sbref0505","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.brainresbull.2016.05.006","article-title":"GABAB receptors in the hippocampal dentate gyrus are involved in spatial learning and memory impairment in a rat model of vascular dementia","volume":"124","author":"Li","year":"2016","journal-title":"Brain Res Bull"},{"key":"10.1016\/j.coph.2017.02.001_sbref0510","doi-asserted-by":"publisher","first-page":"7608","DOI":"10.1038\/srep07608","article-title":"Combining two repurposed drugs as a promising approach for Alzheimer\u2019s disease therapy","volume":"5","author":"Chumakov","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.coph.2017.02.001_bib0515","doi-asserted-by":"publisher","first-page":"P1061","DOI":"10.1016\/j.jalz.2016.06.2216","article-title":"Cognitive event-related potentials used as biomarkers in Pleodial-I study: first evidence of a neurophysiological effect of PXT864 in mild Alzheimer\u2019s disease patients","volume":"12","author":"Bennys","year":"2016","journal-title":"Alzheimer\u2019s Dement J Alzheimer\u2019s Assoc"},{"key":"10.1016\/j.coph.2017.02.001_bib0520","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/0169-328X(94)90223-2","article-title":"Distribution of the serotonin 5-HT2 receptor family mRNAs: comparison between 5-HT2A and 5-HT2C receptors","volume":"23","author":"Pompeiano","year":"1994","journal-title":"Brain Res Mol Brain Res"},{"key":"10.1016\/j.coph.2017.02.001_bib0525","doi-asserted-by":"publisher","first-page":"289","DOI":"10.3389\/fphar.2015.00289","article-title":"Hippocampal 5-HT1A receptor and spatial learning and memory","volume":"6","author":"Glikmann-Johnston","year":"2015","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.coph.2017.02.001_bib0530","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1093\/brain\/awp069","article-title":"Increased binding to 5-HT1A and 5-HT2A receptors is associated with large vessel infarction and relative preservation of cognition","volume":"132","author":"Elliott","year":"2009","journal-title":"Brain"},{"key":"10.1016\/j.coph.2017.02.001_bib0535","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1159\/000088494","article-title":"Donepezil in vascular dementia: combined analysis of two large-scale clinical trials","volume":"20","author":"Roman","year":"2005","journal-title":"Dement Geriatr Cogn Disord"},{"key":"10.1016\/j.coph.2017.02.001_bib0540","first-page":"327","article-title":"Vascular dementia: pharmacological treatment approaches and perspectives","volume":"2","author":"Baskys","year":"2007","journal-title":"Clin Interv Aging"},{"issue":"Suppl. 1","key":"10.1016\/j.coph.2017.02.001_bib0545","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1111\/jnc.13691","article-title":"The clinical symptoms of Parkinson\u2019s disease","volume":"139","author":"Sveinbjornsdottir","year":"2016","journal-title":"J Neurochem"},{"key":"10.1016\/j.coph.2017.02.001_bib0550","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1212\/WNL.0b013e3181f39d0e","article-title":"Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis","volume":"75","author":"Aarsland","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.coph.2017.02.001_sbref0555","doi-asserted-by":"publisher","DOI":"10.1038\/npjparkd.2015.27","article-title":"Different PD-MCI criteria and risk of dementia in Parkinson\u2019s disease: 4-year longitudinal study","author":"Wood","year":"2016","journal-title":"npj Parkinson\u2019s Dis"},{"key":"10.1016\/j.coph.2017.02.001_bib0560","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1002\/mds.21956","article-title":"The Sydney multicenter study of Parkinson\u2019s disease: the inevitability of dementia at 20 years","volume":"23","author":"Hely","year":"2008","journal-title":"Mov Disord"},{"key":"10.1016\/j.coph.2017.02.001_bib0565","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.3174\/ajnr.A4055","article-title":"Subcortical atrophy is associated with cognitive impairment in mild Parkinson disease: a combined investigation of volumetric changes, cortical thickness, and vertex-based shape analysis","volume":"35","author":"Mak","year":"2014","journal-title":"AJNR Am J Neuroradiol"},{"key":"10.1016\/j.coph.2017.02.001_sbref0570","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1093\/brain\/awu036","article-title":"Mild cognitive impairment is linked with faster rate of cortical thinning in patients with Parkinson\u2019s disease longitudinally","volume":"137","author":"Hanganu","year":"2014","journal-title":"Brain"},{"key":"10.1016\/j.coph.2017.02.001_bib0575","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1124\/pr.110.002642","article-title":"The physiology, signaling, and pharmacology of dopamine receptors","volume":"63","author":"Beaulieu","year":"2011","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.coph.2017.02.001_bib0580","first-page":"403039","article-title":"Dopamine receptors and Parkinson\u2019s disease","volume":"2011","author":"Hisahara","year":"2011","journal-title":"Int J Med Chem"},{"key":"10.1016\/j.coph.2017.02.001_bib0585","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/sj.npp.1301073","article-title":"Differential roles of dopamine D1 and D2 receptors in the nucleus accumbens in attentional performance on the five-choice serial reaction time task","volume":"32","author":"Pezze","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.coph.2017.02.001_sbref0590","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1038\/mp.2014.92","article-title":"Local inactivation of Gpr88 in the nucleus accumbens attenuates behavioral deficits elicited by the neonatal administration of phencyclidine in rats","volume":"20","author":"Ingallinesi","year":"2015","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.coph.2017.02.001_bib0595","first-page":"63","article-title":"MRI atrophy parameters related to cognitive and motor impairment in Parkinson\u2019s disease","volume":"16","author":"Alegret","year":"2001","journal-title":"Neurologia"},{"key":"10.1016\/j.coph.2017.02.001_bib0600","first-page":"S23","article-title":"Motor response complications and the function of striatal efferent systems","volume":"43","author":"Chase","year":"1993","journal-title":"Neurology"},{"issue":"Suppl. 4","key":"10.1016\/j.coph.2017.02.001_bib0605","doi-asserted-by":"publisher","first-page":"S44","DOI":"10.1016\/S1353-8020(09)70835-1","article-title":"Role of dopamine receptor agonists in the treatment of early Parkinson\u2019s disease","volume":"15","author":"Bonuccelli","year":"2009","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.coph.2017.02.001_bib0610","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1358\/dot.2010.46.7.1463530","article-title":"Rotigotine transdermal patch for the treatment of Parkinson\u2019s disease and restless legs syndrome","volume":"46","author":"Boroojerdi","year":"2010","journal-title":"Drugs Today (Barc)"},{"key":"10.1016\/j.coph.2017.02.001_bib0615","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1136\/jnnp.68.6.685","article-title":"Dopamine agonists: their role in the treatment of Parkinson\u2019s disease","volume":"68","author":"Brooks","year":"2000","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.coph.2017.02.001_sbref0620","series-title":"The Adenosinergic System: A Non-Dopaminergic Target in Parkinson\u2019s Disease","first-page":"273","article-title":"The story of istradefylline\u2014the first approved A2A antagonist for the treatment of Parkinson\u2019s disease","author":"Mori","year":"2015"},{"key":"10.1016\/j.coph.2017.02.001_bib0625","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ejphar.2015.09.028","article-title":"The adenosine A2A receptor antagonist, istradefylline enhances anti-parkinsonian activity induced by combined treatment with low doses of L-DOPA and dopamine agonists in MPTP-treated common marmosets","volume":"766","author":"Uchida","year":"2015","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.coph.2017.02.001_bib0630","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/j.1755-5949.2010.00142.x","article-title":"Acetylcholine-dopamine interactions in the pathophysiology and treatment of CNS disorders","volume":"16","author":"Lester","year":"2010","journal-title":"CNS Neurosci Ther"},{"key":"10.1016\/j.coph.2017.02.001_bib0635","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.ejphar.2011.01.018","article-title":"Antipsychotic-induced catalepsy is attenuated in mice lacking the M4 muscarinic acetylcholine receptor","volume":"656","author":"Fink-Jensen","year":"2011","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.coph.2017.02.001_bib0640","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/S1474-4422(12)70152-7","article-title":"Cognitive impairment in patients with Parkinson\u2019s disease: diagnosis, biomarkers, and treatment","volume":"11","author":"Svenningsson","year":"2012","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.coph.2017.02.001_bib0645","doi-asserted-by":"publisher","first-page":"10189","DOI":"10.1073\/pnas.0403661101","article-title":"Altered dopamine signaling and MPTP resistance in mice lacking the Parkinson\u2019s disease-associated GPR37\/parkin-associated endothelin-like receptor","volume":"101","author":"Marazziti","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coph.2017.02.001_bib0650","doi-asserted-by":"publisher","first-page":"e60314","DOI":"10.1371\/journal.pone.0060314","article-title":"GPR55, a G-protein coupled receptor for lysophosphatidylinositol, plays a role in motor coordination","volume":"8","author":"Wu","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.coph.2017.02.001_bib0655","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.bbr.2015.04.001","article-title":"Adenosine A2A receptor-mediated control of pilocarpine-induced tremulous jaw movements is Parkinson\u2019s disease-associated GPR37 receptor-dependent","volume":"288","author":"Gandia","year":"2015","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.coph.2017.02.001_bib0660","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1523\/JNEUROSCI.11-06-01649.1991","article-title":"Chronic quinolinic acid lesions in rats closely resemble Huntington\u2019s disease","volume":"11","author":"Beal","year":"1991","journal-title":"J Neurosci"},{"key":"10.1016\/j.coph.2017.02.001_bib0665","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1038\/srep00926","article-title":"Group II metabotropic glutamate receptors modify N-methyl-d-aspartate receptors via Src kinase","volume":"3","author":"Trepanier","year":"2013","journal-title":"Sci Rep"},{"key":"10.1016\/j.coph.2017.02.001_bib0670","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1016\/S0028-3908(00)00079-4","article-title":"Selective blockade of metabotropic glutamate receptor subtype 5 is neuroprotective","volume":"39","author":"Bruno","year":"2000","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.coph.2017.02.001_bib0675","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.brainres.2004.06.005","article-title":"The metabotropic glutamate receptor 5 antagonist MPEP and the mGluR2 agonist LY379268 modify disease progression in a transgenic mouse model of Huntington\u2019s disease","volume":"1019","author":"Schiefer","year":"2004","journal-title":"Brain Res"},{"key":"10.1016\/j.coph.2017.02.001_sbref0680","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.05449","article-title":"A striatal-enriched intronic GPCR modulates huntingtin levels and toxicity","volume":"4","author":"Yao","year":"2015","journal-title":"Elife"},{"key":"10.1016\/j.coph.2017.02.001_bib0685","doi-asserted-by":"publisher","first-page":"114","DOI":"10.3389\/fnins.2013.00114","article-title":"Dopamine imbalance in Huntington\u2019s disease: a mechanism for the lack of behavioral flexibility","volume":"7","author":"Chen","year":"2013","journal-title":"Front Neurosci"},{"key":"10.1016\/j.coph.2017.02.001_bib0690","doi-asserted-by":"publisher","first-page":"12218","DOI":"10.1073\/pnas.0502698102","article-title":"Unraveling a role for dopamine in Huntington\u2019s disease: the dual role of reactive oxygen species and D2 receptor stimulation","volume":"102","author":"Charvin","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coph.2017.02.001_bib0695","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.nbd.2007.07.028","article-title":"Haloperidol protects striatal neurons from dysfunction induced by mutated huntingtin in vivo","volume":"29","author":"Charvin","year":"2008","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.coph.2017.02.001_bib0700","doi-asserted-by":"publisher","first-page":"7899","DOI":"10.1523\/JNEUROSCI.1396-07.2007","article-title":"Dopaminergic signaling and striatal neurodegeneration in Huntington\u2019s disease","volume":"27","author":"Tang","year":"2007","journal-title":"J Neurosci"},{"key":"10.1016\/j.coph.2017.02.001_bib0705","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1038\/nm.f.1869","article-title":"Endocannabinoid signaling as a synaptic circuit breaker in neurological disease","volume":"14","author":"Katona","year":"2008","journal-title":"Nat Med"},{"key":"10.1016\/j.coph.2017.02.001_bib0710","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/brain\/awq278","article-title":"Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington\u2019s disease","volume":"134","author":"Blazquez","year":"2011","journal-title":"Brain"},{"key":"10.1016\/j.coph.2017.02.001_bib0715","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1111\/j.1476-5381.2010.00773.x","article-title":"Neuroprotective potential of CB1 receptor agonists in an in vitro model of Huntington\u2019s disease","volume":"160","author":"Scotter","year":"2010","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.coph.2017.02.001_bib0720","first-page":"1380","article-title":"Adenosine receptors and brain diseases: neuroprotection and neurodegeneration","volume":"2011","author":"Gomes","year":"1808","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.coph.2017.02.001_bib0725","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1002\/jnr.20138","article-title":"Adenosine A2A receptor blockade differentially influences excitotoxic mechanisms at pre- and postsynaptic sites in the rat striatum","volume":"77","author":"Tebano","year":"2004","journal-title":"J Neurosci Res"},{"key":"10.1016\/j.coph.2017.02.001_bib0730","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1111\/j.1471-4159.2005.03029.x","article-title":"CGS21680 attenuates symptoms of Huntington\u2019s disease in a transgenic mouse model","volume":"93","author":"Chou","year":"2005","journal-title":"J Neurochem"},{"key":"10.1016\/j.coph.2017.02.001_bib0735","doi-asserted-by":"publisher","first-page":"369","DOI":"10.5483\/BMBRep.2014.47.7.086","article-title":"Neuroprotective roles of pituitary adenylate cyclase-activating polypeptide in neurodegenerative diseases","volume":"47","author":"Lee","year":"2014","journal-title":"BMB Rep"},{"key":"10.1016\/j.coph.2017.02.001_bib0740","doi-asserted-by":"publisher","first-page":"661","DOI":"10.2174\/187152710793361595","article-title":"Therapeutic potential of vasoactive intestinal peptide and its receptors in neurological disorders","volume":"9","author":"White","year":"2010","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"10.1016\/j.coph.2017.02.001_bib0745","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1097\/FBP.0b013e3283566082","article-title":"Pimavanserin, a 5-HT2A receptor inverse agonist, reverses psychosis-like behaviors in a rodent model of Alzheimer\u2019s disease","volume":"23","author":"Price","year":"2012","journal-title":"Behav Pharmacol"},{"key":"10.1016\/j.coph.2017.02.001_bib0750","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0031-6997(24)01483-2","article-title":"Antipsychotic drugs: importance of dopamine receptors for mechanisms of therapeutic actions and side effects","volume":"53","author":"Strange","year":"2001","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.coph.2017.02.001_bib0755","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.nbd.2010.09.021","article-title":"A2A receptor knockout worsens survival and motor behaviour in a transgenic mouse model of Huntington\u2019s disease","volume":"41","author":"Mievis","year":"2011","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.coph.2017.02.001_bib0760","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.pneurobio.2006.12.005","article-title":"Functions, dysfunctions and possible therapeutic relevance of adenosine A2A receptors in Huntington\u2019s disease","volume":"81","author":"Popoli","year":"2007","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.coph.2017.02.001_bib0765","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.neuroscience.2013.12.018","article-title":"Modulation of synaptic transmission by adenosine in layer 2\/3 of the rat visual cortex in vitro","volume":"260","author":"Bannon","year":"2014","journal-title":"Neuroscience"},{"key":"10.1016\/j.coph.2017.02.001_bib0770","doi-asserted-by":"publisher","first-page":"14078","DOI":"10.1073\/pnas.1512812112","article-title":"Allosteric activation of M4 muscarinic receptors improve behavioral and physiological alterations in early symptomatic YAC128 mice","volume":"112","author":"Pancani","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coph.2017.02.001_sbref0775","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.1093\/hmg\/ddt598","article-title":"Metabotropic glutamate receptor 5 knockout promotes motor and biochemical alterations in a mouse model of Huntington\u2019s disease","volume":"23","author":"Ribeiro","year":"2014","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.coph.2017.02.001_bib0780","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1172\/JCI74603","article-title":"BAI1 regulates spatial learning and synaptic plasticity in the hippocampus","volume":"125","author":"Zhu","year":"2015","journal-title":"J Clin Invest"},{"key":"10.1016\/j.coph.2017.02.001_bib0785","doi-asserted-by":"publisher","first-page":"13668","DOI":"10.1073\/pnas.1835724100","article-title":"Allosteric modulation of group III metabotropic glutamate receptor 4: a potential approach to Parkinson\u2019s disease treatment","volume":"100","author":"Marino","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coph.2017.02.001_bib0790","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1124\/mol.108.049551","article-title":"Discovery, characterization, and antiparkinsonian effect of novel positive allosteric modulators of metabotropic glutamate receptor 4","volume":"74","author":"Niswender","year":"2008","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.coph.2017.02.001_bib0795","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1017\/S1461145713001314","article-title":"Protective effect of pranlukast on Abeta(1)(\u2212)(4)(2)-induced cognitive deficits associated with downregulation of cysteinyl leukotriene receptor 1","volume":"17","author":"Tang","year":"2014","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.coph.2017.02.001_bib0800","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1038\/cr.2010.3","article-title":"A GPCR\/secretase complex regulates beta- and gamma-secretase specificity for Abeta production and contributes to AD pathogenesis","volume":"20","author":"Teng","year":"2010","journal-title":"Cell Res"},{"key":"10.1016\/j.coph.2017.02.001_bib0805","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neubiorev.2016.01.007","article-title":"Role of GABA(B) receptors in learning and memory and neurological disorders","volume":"63","author":"Heaney","year":"2016","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1016\/j.coph.2017.02.001_bib0810","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1152\/jn.00866.2010","article-title":"Glucose-dependent insulinotropic polypeptide receptor knockout mice are impaired in learning, synaptic plasticity, and neurogenesis","volume":"105","author":"Faivre","year":"2011","journal-title":"J Neurophysiol"},{"key":"10.1016\/j.coph.2017.02.001_bib0815","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.jphs.2016.06.005","article-title":"Ameliorative effect of membrane-associated estrogen receptor G protein coupled receptor 30 activation on object recognition memory in mouse models of Alzheimer\u2019s disease","volume":"131","author":"Kubota","year":"2016","journal-title":"J Pharmacol Sci"},{"key":"10.1016\/j.coph.2017.02.001_bib0820","doi-asserted-by":"publisher","first-page":"8767","DOI":"10.1074\/jbc.M113.530816","article-title":"LGR4\/GPR48 inactivation leads to aniridia-genitourinary anomalies-mental retardation syndrome defects","volume":"289","author":"Yi","year":"2014","journal-title":"J Biol Chem"},{"key":"10.1016\/j.coph.2017.02.001_bib0825","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.neuron.2006.01.020","article-title":"M1 receptors play a central role in modulating AD-like pathology in transgenic mice","volume":"49","author":"Caccamo","year":"2006","journal-title":"Neuron"},{"key":"10.1016\/j.coph.2017.02.001_bib0830","doi-asserted-by":"publisher","first-page":"9440","DOI":"10.1073\/pnas.0914801107","article-title":"The M3-muscarinic receptor regulates learning and memory in a receptor phosphorylation\/arrestin-dependent manner","volume":"107","author":"Poulin","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coph.2017.02.001_bib0835","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1007\/s12031-013-9979-6","article-title":"FTY720 (fingolimod) attenuates beta-amyloid peptide (Abeta42)-induced impairment of spatial learning and memory in rats","volume":"50","author":"Asle-Rousta","year":"2013","journal-title":"J Mol Neurosci"}],"container-title":["Current Opinion in Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489217300243?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489217300243?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T17:47:54Z","timestamp":1750096074000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471489217300243"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":167,"alternative-id":["S1471489217300243"],"URL":"https:\/\/doi.org\/10.1016\/j.coph.2017.02.001","relation":{},"ISSN":["1471-4892"],"issn-type":[{"value":"1471-4892","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of GPCRs in neurodegenerative diseases: avenues for therapeutic intervention","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coph.2017.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}